指南与共识消化、代谢与肾脏急症

巴西指南:疑似或确诊COVID-19门诊患者的药物治疗

Brazilian guidelines for the treatment of outpatients with suspected or confirmed COVID-19. A joint guideline of the Brazilian Association of Emergency Medicine (ABRAMEDE), Brazilian Medical Association (AMB), Brazilian Society of Angiology and Vascular Surgery (SBACV), Brazilian Society of Geriatrics and Gerontology (SBGG), Brazilian Society of Infectious Diseases (SBI), Brazilian Society of Fami
指南 / 共识 · Braz J Infect Dis · 2022-03-17
一句话结论巴西多学会联合指南基于GRADE方法明确反对门诊使用抗凝药、阿奇霉素、布地奈德、秋水仙碱、糖皮质激素、羟氯喹/氯喹、伊维菌素、硝唑尼特和恢复期血浆治疗COVID-19。

该指南由巴西急诊医学协会(ABRAMEDE)、巴西医学会(AMB)、巴西血管外科与血管病学会(SBACV)、巴西老年医学与老年学学会(SBGG)、巴西感染病学会(SBI)、巴西家庭与社区医学会等联合制定,专家组共37人,包括不同临床领域专家、巴西卫生部代表和方法学家。采用快速指南制定方法(GRADE-ADOLOPMENT),在采纳和/或改编现有国际指南推荐的基础上,结合结构化检索原始研究,必要时形成新推荐;证据质量评级和推荐撰写遵循GRADE方法。共评估10种技术,形成10条推荐,均为反对使用抗凝药、阿奇霉素、布地奈德、秋水仙碱、糖皮质激素、羟氯喹/氯喹(单用或联用阿奇霉素)、伊维菌素、硝唑尼特和恢复期血浆。关于门诊使用单克隆抗体,因获益不确定、成本高且可及性和实施受限,未能形成推荐。结论指出迄今少数疗法显示对COVID-19门诊患者有效,推荐仅限于不应使用的内容,以提供符合循证医学原则的最佳治疗,并通过避免无效治疗促进资源节约。

要点

  • 指南反对门诊使用抗凝药治疗COVID-19。
  • 指南反对门诊使用阿奇霉素、羟氯喹/氯喹(单用或联用阿奇霉素)、伊维菌素、硝唑尼特。
  • 指南反对门诊使用布地奈德、秋水仙碱、糖皮质激素、恢复期血浆。
  • 门诊单克隆抗体因获益不确定、成本高且可及性和实施受限,未能形成推荐。

适用人群与场景

  • 巴西的门诊COVID-19疑似或确诊患者。

处置流程与药物剂量

  • 反对使用抗凝药。
  • 反对使用阿奇霉素。
  • 反对使用布地奈德。
  • 反对使用秋水仙碱。
  • 反对使用糖皮质激素。
  • 反对使用羟氯喹/氯喹,单用或联用阿奇霉素。
  • 反对使用伊维菌素。
  • 反对使用硝唑尼特。

研究设计与关键结果

  • 指南制定专家组共37人,包括不同临床领域专家、巴西卫生部代表和方法学家。
  • 采用快速指南制定方法(GRADE-ADOLOPMENT),基于采纳和/或改编现有国际指南推荐,结合结构化检索原始研究,必要时形成新推荐;证据质量评级和推荐撰写遵循GRADE方法。
  • 共评估10种技术,形成10条推荐,均为反对使用抗凝药、阿奇霉素、布地奈德、秋水仙碱、糖皮质激素、羟氯喹/氯喹(单用或联用阿奇霉素)、伊维菌素、硝唑尼特和恢复期血浆。
  • 关于门诊使用单克隆抗体,因获益不确定、成本高且可及性和实施受限,未能形成推荐。

证据类型、等级与局限

  • 证据类型:指南(GRADE-ADOLOPMENT方法,GRADE分级)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 指南反对门诊使用抗凝药、阿奇霉素、布地奈德、秋水仙碱、糖皮质激素、羟氯喹/氯喹(单用或联用阿奇霉素)、伊维菌素、硝唑尼特和恢复期血浆,以提供符合循证医学原则的最佳治疗并避免无效治疗、促进资源节约。
  • 门诊单克隆抗体的获益不确定、成本高且可及性和实施受限,未能形成推荐。

指南或共识出处

  • 指南名称:Brazilian guidelines for the treatment of outpatients with suspected or confirmed COVID-19。
  • 发布机构:巴西急诊医学协会(ABRAMEDE)、巴西医学会(AMB)、巴西血管外科与血管病学会(SBACV)、巴西老年医学与老年学学会(SBGG)、巴西感染病学会(SBI)、巴西家庭与社区医学会等联合制定。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Several therapies have been used or proposed for the treatment of COVID-19, although their effectiveness and safety have not been properly evaluated. The purpose of this document is to provide recommendations to support decisions about the drug treatment of outpatients with COVID-19 in Brazil.

METHODS: A panel consisting of experts from different clinical fields, representatives of the Brazilian Ministry of Health, and methodologists (37 members in total) was responsible for preparing these guidelines. A rapid guideline development method was used, based on the adoption and/or adaptation of recommendations from existing international guidelines combined with additional structured searches for primary studies and new recommendations whenever necessary (GRADE-ADOLOPMENT). The rating of quality of evidence and the drafting of recommendations followed the GRADE method.

RESULTS: Ten technologies were evaluated, and 10 recommendations were prepared. Recommendations were made against the use of anticoagulants, azithromycin, budesonide, colchicine, corticosteroids, hydroxychloroquine/chloroquine alone or combined with azithromycin, ivermectin, nitazoxanide, and convalescent plasma. It was not possible to make a recommendation regarding the use of monoclonal antibodies in outpatients, as their benefit is uncertain and their cost is high, with limitations of availability and implementation.

CONCLUSION: To date, few therapies have demonstrated effectiveness in the treatment of outpatients with COVID-19. Recommendations are restricted to what should not be used, in order to provide the best treatment according to the principles of evidence-based medicine and to promote resource savings by aboiding ineffective treatments.

来源:Braz J Infect Dis,查看原文。版权归原作者所有。

参考来源

  1. Falavigna M, Belli KC, Barbosa AN, et al. Brazilian guidelines for the treatment of outpatients with suspected or confirmed COVID-19. A joint guideline of the Brazilian Association of Emergency Medicine (ABRAMEDE), Brazilian Medical Association (AMB), Brazilian Society of Angiology and Vascular Surgery (SBACV), Brazilian Society of Geriatrics and Gerontology (SBGG), Brazilian Society of Infectious Diseases (SBI), Brazilian Society of Family and Community Medicine (SBFMC), and Brazilian Thoracic Society (SBPT). Braz J Infect Dis. 2022. PMID: 35341739. doi:10.1016/j.bjid.2022.102347

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。